vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and CPI AEROSTRUCTURES INC (CVU). Click either name above to swap in a different company.
CPI AEROSTRUCTURES INC is the larger business by last-quarter revenue ($19.4M vs $15.0M, roughly 1.3× CHAMPIONS ONCOLOGY, INC.). CPI AEROSTRUCTURES INC runs the higher net margin — 3.6% vs 1.8%, a 1.8% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs -10.8%). CHAMPIONS ONCOLOGY, INC. produced more free cash flow last quarter ($-2.0M vs $-2.1M). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs 0.9%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
CPI Aerostructures Inc., known as CPI Aero, is a contract aircraft component manufacturer based in Edgewood, New York.
CSBR vs CVU — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $19.4M |
| Net Profit | $268.0K | $691.8K |
| Gross Margin | 51.7% | 20.3% |
| Operating Margin | 1.2% | 6.4% |
| Net Margin | 1.8% | 3.6% |
| Revenue YoY | 11.5% | -10.8% |
| Net Profit YoY | -63.2% | -28.8% |
| EPS (diluted) | $0.02 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $19.4M | ||
| Q3 25 | $14.0M | $19.3M | ||
| Q2 25 | $12.4M | $15.2M | ||
| Q1 25 | $17.0M | $15.4M | ||
| Q4 24 | $13.5M | $21.8M | ||
| Q3 24 | $14.1M | $19.4M | ||
| Q2 24 | $14.0M | $20.8M | ||
| Q1 24 | $12.0M | $19.1M |
| Q4 25 | $268.0K | $691.8K | ||
| Q3 25 | $-436.0K | $1.1M | ||
| Q2 25 | $-1.8M | $-1.3M | ||
| Q1 25 | $4.5M | $-1.3M | ||
| Q4 24 | $728.0K | $971.5K | ||
| Q3 24 | $1.3M | $749.7K | ||
| Q2 24 | $-109.0K | $1.4M | ||
| Q1 24 | $-2.5M | $168.2K |
| Q4 25 | 51.7% | 20.3% | ||
| Q3 25 | 42.9% | 22.3% | ||
| Q2 25 | 41.1% | 4.4% | ||
| Q1 25 | 61.2% | 10.7% | ||
| Q4 24 | 44.9% | 20.0% | ||
| Q3 24 | 49.7% | 21.7% | ||
| Q2 24 | 48.2% | 24.6% | ||
| Q1 24 | 34.7% | 18.6% |
| Q4 25 | 1.2% | 6.4% | ||
| Q3 25 | -3.8% | 9.1% | ||
| Q2 25 | -16.2% | -13.1% | ||
| Q1 25 | 26.4% | -7.7% | ||
| Q4 24 | 5.4% | 9.5% | ||
| Q3 24 | 9.5% | 7.6% | ||
| Q2 24 | -1.9% | 11.2% | ||
| Q1 24 | -21.4% | 4.4% |
| Q4 25 | 1.8% | 3.6% | ||
| Q3 25 | -3.1% | 5.8% | ||
| Q2 25 | -14.9% | -8.7% | ||
| Q1 25 | 26.4% | -8.6% | ||
| Q4 24 | 5.4% | 4.5% | ||
| Q3 24 | 9.3% | 3.9% | ||
| Q2 24 | -0.8% | 6.8% | ||
| Q1 24 | -21.1% | 0.9% |
| Q4 25 | $0.02 | $0.04 | ||
| Q3 25 | $-0.03 | $0.09 | ||
| Q2 25 | $-0.12 | $-0.10 | ||
| Q1 25 | $0.31 | $-0.10 | ||
| Q4 24 | $0.05 | $0.08 | ||
| Q3 24 | $0.09 | $0.06 | ||
| Q2 24 | $-0.01 | $0.11 | ||
| Q1 24 | $-0.19 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | — |
| Total DebtLower is stronger | — | $0 |
| Stockholders' EquityBook value | $4.2M | $25.8M |
| Total Assets | $30.2M | $75.2M |
| Debt / EquityLower = less leverage | — | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | — | ||
| Q3 25 | $10.3M | — | ||
| Q2 25 | $9.8M | — | ||
| Q1 25 | $3.2M | — | ||
| Q4 24 | $2.8M | — | ||
| Q3 24 | $2.9M | — | ||
| Q2 24 | $2.6M | — | ||
| Q1 24 | $4.5M | — |
| Q4 25 | — | $0 | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $26.5K | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $4.2M | $25.8M | ||
| Q3 25 | $3.5M | $25.0M | ||
| Q2 25 | $3.8M | $23.8M | ||
| Q1 25 | $5.5M | $24.9M | ||
| Q4 24 | $681.0K | $25.9M | ||
| Q3 24 | $-332.0K | $24.9M | ||
| Q2 24 | $-1.9M | $24.1M | ||
| Q1 24 | $-2.1M | $22.5M |
| Q4 25 | $30.2M | $75.2M | ||
| Q3 25 | $30.5M | $74.1M | ||
| Q2 25 | $32.3M | $72.3M | ||
| Q1 25 | $30.6M | $65.4M | ||
| Q4 24 | $25.2M | $68.0M | ||
| Q3 24 | $24.9M | $68.9M | ||
| Q2 24 | $26.1M | $70.2M | ||
| Q1 24 | $26.8M | $70.8M |
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-2.1M |
| Free Cash FlowOCF − Capex | $-2.0M | $-2.1M |
| FCF MarginFCF / Revenue | -13.1% | -10.8% |
| Capex IntensityCapex / Revenue | 1.6% | 0.0% |
| Cash ConversionOCF / Net Profit | -6.47× | -3.03× |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $-5.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $-2.1M | ||
| Q3 25 | $600.0K | $212.1K | ||
| Q2 25 | $6.9M | $-596.3K | ||
| Q1 25 | $490.0K | $-2.7M | ||
| Q4 24 | $-283.0K | $4.4M | ||
| Q3 24 | $311.0K | $715.1K | ||
| Q2 24 | $-1.8M | $-591.7K | ||
| Q1 24 | $-919.0K | $-960.5K |
| Q4 25 | $-2.0M | $-2.1M | ||
| Q3 25 | $554.0K | $211.1K | ||
| Q2 25 | $6.6M | $-599.8K | ||
| Q1 25 | $448.0K | $-2.8M | ||
| Q4 24 | $-377.0K | $4.3M | ||
| Q3 24 | — | $586.9K | ||
| Q2 24 | $-1.8M | $-746.9K | ||
| Q1 24 | $-1.0M | $-1.0M |
| Q4 25 | -13.1% | -10.8% | ||
| Q3 25 | 4.0% | 1.1% | ||
| Q2 25 | 53.5% | -4.0% | ||
| Q1 25 | 2.6% | -18.1% | ||
| Q4 24 | -2.8% | 19.9% | ||
| Q3 24 | — | 3.0% | ||
| Q2 24 | -13.0% | -3.6% | ||
| Q1 24 | -8.4% | -5.3% |
| Q4 25 | 1.6% | 0.0% | ||
| Q3 25 | 0.3% | 0.0% | ||
| Q2 25 | 2.0% | 0.0% | ||
| Q1 25 | 0.2% | 0.4% | ||
| Q4 24 | 0.7% | 0.3% | ||
| Q3 24 | 0.0% | 0.7% | ||
| Q2 24 | 0.0% | 0.7% | ||
| Q1 24 | 0.8% | 0.2% |
| Q4 25 | -6.47× | -3.03× | ||
| Q3 25 | — | 0.19× | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | 4.53× | ||
| Q3 24 | 0.24× | 0.95× | ||
| Q2 24 | — | -0.42× | ||
| Q1 24 | — | -5.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
CVU
| Government Subcontracts | $16.4M | 85% |
| Commercial Contracts | $2.3M | 12% |
| Prime Government Contracts | $725.8K | 4% |
